LIFECORE BIOMEDICAL, INC. \DE\ (LFCR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 a2026stockincentiveplan.htm EX-10.1 Document Exhibit 10.1 LIFECORE BIOMEDICAL, INC. 2026 STOCK INCENTIVE PLAN SECTION 1. INTRODUCTION. 1.1 The Lifecore Biomedical, Inc. 2026 Stock Incentive Plan (the “Plan”) will be effective on October 16, 2026 (the “Effective Date”),
How this was made
The 30-second read
Why it matters
The plan would supersede the existing equity plan upon an October 16, 2026 effective date, subject to stockholder approval within one year; if approval fails, no awards are made under the new plan and the existing plan continues.
Market read
Traders should treat this as a governance/compensation update with potential dilution implications, not as an earnings/operational catalyst.
What to watch
Key sensitivity is the size of future awards and expected dilution; this filing text excerpt doesn’t quantify award volumes or grant schedules.
Background
The 8-K includes Item 5.02 (director/officer changes and compensatory arrangements) and Item 5.07 (matters submitted to a vote), with Exhibit 10.1 describing the Lifecore Biomedical 2026 Stock Incentive Plan.
Ticker impact
Lifecore Biomedical filed an 8-K with its 2026 Stock Incentive Plan and related director/officer appointment and voting matters.
Likely limited near-term price impact; any reaction would be driven by investor sensitivity to potential future dilution rather than new operating fundamentals.
The disclosure is primarily corporate governance/compensation-plan mechanics (effective date, stockholder approval condition, award types) without new revenue/earnings guidance or deal/clinical catalysts.
Market effects
Minimal sector read-through; equity incentive plan mechanics are company-specific.
None.
None.
Counterpoint
Investors may overreact to the headline “new plan,” but the plan’s impact depends on whether stockholders approve and how much equity is actually granted later.
Key entities
- issuerLifecore Biomedical, Inc.
Company filing the 8-K and adopting the 2026 Stock Incentive Plan subject to stockholder approval.
- compensation_plan2026 Stock Incentive Plan
Provides discretionary awards (options, SARs, stock grants, stock units) and includes cashless exercise and change-in-control definitions.
